In the ongoing effort to contain the impact of the coronavirus pandemic, clinical trials are underway to test several drugs for their effectiveness as potential COVID-19 treatments.
A randomized, placebo-controlled, double-blind trial of a drug initially developed to treat Ebola is on clinical trial at Northwestern Medicine in Illinois. Similar trials are being done by Cedars-Sinai and the University of California-Davis. The trio are part of a larger global trial project, sponsored by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH), to help find a COVID-19 treatment.
Northwestern Medicine has enrolled its first participants in a new international clinical drug trial for COVID-19. The drug being tested is remdesivir, a novel anti-viral drug developed to treat Ebola and which has subsequently been found, in animal models, to have antiviral activity against coronaviruses including MERS and now SARS-Cov-2, the virus that causes COVID-19 disease.
Cedars-Sinai has joined an international effort to test an experimental antiviral drug as a potential treatment for COVID-19 (coronavirus). The institution expects to enroll its first clinical trial participant this week.
Cedars-Sinai is among dozens of sites around the world participating in the clinical trial, sponsored by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH). The trial is evaluating remdesivir, an investigational drug developed by the biopharmaceutical company Gilead Sciences Inc., based in Foster City, California.
UC Davis Health has two clinical trials underway for hospitalized patients with severe COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2.
The studies are evaluating the safety and effectiveness of two drugs — the investigational antiviral remdesivir, and sarilumab, a drug that blocks the body's acute inflammatory response.
Read more about each trial here: